Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (NCT06087458) | Clinical Trial Compass
RecruitingPhase 1/2
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
United States60 participantsStarted 2023-06-21
Plain-language summary
The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.
Who can participate
Age range60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Are ≥60 years of age at the time of consent.
* Are willing and able to understand and provide written informed consent.
* Are willing and able to return for scheduled treatment and follow-up examinations.
* Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
* Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.
* Absence of signs of non-exudative MNV.
* Additional Ocular Inclusion Criteria for both eyes.
* Meet certain genotype criteria for risk of AMD.
Exclusion Criteria:
* Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.
* Additional Systemic, Ocular, and Genetic Exclusion Criteria.
What they're measuring
1
Overall effect of treatment on retinal structural health